Recent Story Posts
Innovation
An Open Letter from our Chairman and CEO
Innovation
Making Medicines: We Have Adequate Supply Across our HIV, Hepatitis Portfolios
Innovation
Innovation and Growth in Immuno-Oncology
Recent Press Releases
-
March 19, 2020
U.S. Food And Drug Administration Approves Epclusa® (Sofosbuvir/Velpatasvir) for Children Ages 6 and Older or Weighing at Least 17 kg with Chronic Hepatitis C Infection -
March 11, 2020
New Clinical Study Data for Gilead’s Investigational HIV-1 Capsid Inhibitor GS-6207 Presented at CROI 2020
For more information, contact us.
Phone:
1-800-GILEAD-5 (1-800-445-3235)
1-800-GILEAD-5 (1-800-445-3235)